Ira M Jacobson

Telaprevir for previously untreated chronic hepatitis C virus infection.

Geoffrey Dusheiko, Abdul J Sankoh, Tara L. Kieffer, 2011, The New England journal of medicine.

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Stefan Zeuzem, Norman Gitlin, M. Buti, 2014, The New England journal of medicine.

Sofosbuvir for previously untreated chronic hepatitis C infection.

John McNally, Michael Schultz, A. Mangia, 2013, The New England journal of medicine.

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Stefan Zeuzem, Junyuan Xiong, Edward Tam, 2014, The New England journal of medicine.

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Oliver Lenz, G. Dore, G. Foster, 2014, The Lancet.

Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum α‐fetoprotein

Andrew H Talal, Luis Chiriboga, Herman Yee, 2004, Liver international : official journal of the International Association for the Study of the Liver.

Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection.

Marianthi Markatou, Andrew H Talal, Marija Zeremski, 2009, The Journal of infectious diseases.

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

John F. Flaherty, M. Washington, M. Buti, 2013, The Lancet.

Boceprevir for untreated chronic HCV genotype 1 infection.

M. Manns, J. Albrecht, K. Reddy, 2011, The New England journal of medicine.

Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C.

Andrew H Talal, David Butera, C. Rice, 2005, Blood.